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Since the linking of mutations in the Cu,Zn superoxide dismutase
gene (sod1) to amyotrophic lateral sclerosis (ALS) in 1993, re-
searchers have sought the connection between SOD1 and motor
neuron death. Disease-linked mutations tend to destabilize the
native dimeric structure of SOD1, and plaques containing mis-
folded and aggregated SOD1 have been found in the motor neu-
rons of patients with ALS. Despite advances in understanding of
ALS disease progression and SOD1 folding and stability, cytotoxic
species and mechanisms remain unknown, greatly impeding the
search for and design of therapeutic interventions. Here, we de-
finitively link cytotoxicity associated with SOD1 aggregation in
ALS to a nonnative trimeric SOD1 species. We develop methodol-
ogy for the incorporation of low-resolution experimental data into
simulations toward the structural modeling of metastable, multi-
domain aggregation intermediates. We apply this methodology to
derive the structure of a SOD1 trimer, which we validate in vitro
and in hybridized motor neurons. We show that SOD1 mutants
designed to promote trimerization increase cell death. Further, we
demonstrate that the cytotoxicity of the designed mutants corre-
lates with trimer stability, providing a direct link between the
presence of misfolded oligomers and neuron death. Identification
of cytotoxic species is the first and critical step in elucidating the
molecular etiology of ALS, and the ability to manipulate formation
of these species will provide an avenue for the development of
future therapeutic strategies.
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structural modeling
Protein misfolding and aggregation are linked to cell deathand disease progression in neurodegenerative diseases, such
as Alzheimer’s disease, Parkinson’s disease, and amyotrophic
lateral sclerosis (ALS). In these diseases and others, the formation
of amyloid plaques, often observed post mortem, has long been
thought to play a role in neurodegeneration, but toxicity has never
been confirmed (1–3). Recent research has shown that small, sol-
uble oligomers, rather than insoluble amyloids, are likely to be the
cytotoxic species causing neurodegeneration (4–14). These small,
soluble oligomers undergo aberrant interactions with cell machin-
ery and activate cell death pathways, but their exact stoichiometry is
not known and their properties have yet to be characterized. Re-
cently, metastable soluble Cu,Zn superoxide dismutase (SOD1)
oligomers have been identified that contain an epitope associated
with disease-linked species of SOD1, mutants of which are impli-
cated in a subset of ALS (15–18). Size exclusion chromatography
(SEC) of these oligomers revealed a size range of two to four
monomers, consistent with previous findings of potentially cyto-
toxic SOD1 oligomers (19–21).
Knowledge of the structures of these species would not only
allow for definitive testing of their toxicity but could potentially
lead to an understanding of disease mechanism and therapeutic
strategies against diseases for which no cure or effective treatment
exists (22). By their nature, however, these oligomers are only
metastable, and therefore difficult to isolate. More importantly, this
instability, and consequent transient nature, combined with the
proposed size range of the implicated oligomers, means that a high-
resolution structure cannot be achieved using traditional methods.
Although atomic structures have been explored for folding inter-
mediates of small protein domains (23) or stable oligomeric struc-
tures of disease-relevant peptide sequences (24), structural
characterization of metastable aggregation products of full-length
disease-linked proteins has remained elusive.
Here, we combined experimental and computational ap-
proaches to produce a molecular model of a toxic metastable
protein oligomer. Using state-of-the-art high-speed atomic force
microscopy (HS-AFM), we established the trimeric stoichiome-
try and highly dynamic nature of the isolated oligomers. We
applied limited proteolysis to the isolated SOD1 trimers, allow-
ing us to determine the solvent accessibility and rigidity of the
structure. Using this information as constraints in molecular
simulations, we evolved a structural model of the SOD1 trimer
that is consistent with our experimental data. Using our model,
we determined residues critical to trimer formation, and we used
rational mutagenesis to verify our model and manipulate trimer
formation in vitro and in living cells. We find that mutations that
stabilize the trimeric form of SOD1 result in increased cell death
over WT SOD1 or SOD1 mutants that inhibit trimer formation,
demonstrating the neurotoxicity of the SOD1 trimer and its potential
relevance to ALS etiology.
Significance
Protein aggregation is a hallmark of neurodegenerative dis-
ease and is hypothesized to cause neuron death. Despite ex-
tensive study of disease-associated aggregating proteins,
mechanisms of neuron death remain a mystery, and no cures or
effective treatments yet exist. Here, we demonstrate the tox-
icity of a small aggregate of the Cu,Zn superoxide dismutase
(SOD1) protein, associated with amyotrophic lateral sclerosis
(ALS). We present an experimentally verified structural model
of this toxic species and show that SOD1 mutants designed to
promote formation of this aggregate increase cell death, pro-
viding a direct link between aggregate presence and neuron
death. Knowledge of toxic species and the ability to manipu-
late their formation provides a valuable direction for pursuit of
therapeutic strategies in ALS.
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Results
Determination of SOD1 Oligomer Stoichiometry. To model poten-
tially toxic SOD1 oligomers accurately, we first determined the
number of SOD1 monomers participating in the oligomers using
definitive images obtained by both regular AFM and HS-AFM.
We find that the metastable SOD1 oligomers are stabilized at
pH 3.5, where the SOD1 aggregation pathway has been shown to
proceed more rapidly while retaining the same features and
characteristics as the physiological process. We have demon-
strated previously that although low pH accelerates progression
along the aggregation pathway by stabilizing species further
down that pathway, it does not affect the pathway itself (25). At
pH 3.5, where the SOD1 oligomers are stable, oligomer volume
is ∼71.7 nm3, threefold greater than oligomer volume of the
monomer (∼25.3 nm3; Fig. S1A). These data are supported by
HS-AFM images resolving the three-partite structure of the olig-
omer (Fig. 1A). We conclude that the primary SOD1 oligomer
previously identified by Redler et al. (15) is a trimer. Upon in-
crease of pH to 7.4, where the SOD1 oligomer is less stable, the
majority of trimers dissociate into monomers, as confirmed by
volumetric AFM measurements (Fig. 1B and Fig. S1A). We find
that any larger aggregates encountered at low pH are mainly short
fibrillar structures (Fig. S1B).
SOD1 Trimer Features Nonnative Secondary, Tertiary, and Quaternary
Structure. After purification (26), aggregation, and isolation of the
SOD1 trimer (15), we conducted limited proteolysis, followed by
MS, to identify unstructured, solvent-accessible regions (27). Sev-
eral proteolytic cuts are located in regions that are buried in the
dimer interface or contain secondary structure elements in the
SOD1 dimer (Fig. 2A), which would make proteolysis impossible
or highly unlikely if native secondary and tertiary structure were
conserved. Limited proteolysis of SOD1 dimer and isolated SOD1
monomer demonstrate that the pattern of proteolytic cleavage
differs significantly (Fig. 2B). In addition to secondary and tertiary
structure differences, we conclude from proteolytic data that the
interface(s) between monomers in the SOD1 trimer must be lo-
cated in a different region of the monomer from the native SOD1
dimer interface (i.e., a significant change in quaternary structure).
The SOD1 trimer therefore is not simply the result of an addition
of a “loose”monomer to a preexisting native-like SOD1 dimer, but
features significant rearrangement from the native configuration
and fold that necessitates complete dissociation of the native dimer
and aggregation of partially unfolded monomers, in agreement
with previous findings (25, 28).
To characterize this rearrangement and obtain a structure of
the SOD1 trimer, we performed coarse-grained discrete molec-
ular dynamics (DMD) simulations of three unbound SOD1
monomers with a knowledge-based force field based on the re-
quirement for the experimentally obtained proteolytic cut sites to
be unstructured and solvent-exposed (Fig. S2). We designed our
force field such that native contacts are attractive to each other
and proteolytic cut sites are repulsive to all other residues, ful-
filling the requirements for cleavage and introducing competition
between the native and nonnative states (Fig. S3). After extensive
coarse-grained sampling, followed by equilibration in a physics-
based, all-atom force field (29), we obtained a model of the SOD1
trimer that agrees with experimental results (Fig. 2C andMovie S1):
The majority of identified proteolytic cut sites are surface-exposed
and reside in unstructured regions. Due to competition between the
native fold and the artificially imposed, experimentally derived bias,
not all proteolytic cut sites are surface-exposed in the set of lowest
energy structures, although they are present in the population as a
whole (Dataset S1). We find that, consistent with our conclusions
from limited proteolysis data, the individual monomers in the SOD1
trimer are severely misfolded and deviate significantly, with rmsds
from the native monomer of 12.5 Å, 19.3 Å, and 11.7 Å. More
importantly, as predicted from proteolysis data, the potentially cy-
totoxic SOD1 trimer does not make use of the same monomer–
monomer interface as the native SOD1 dimer. Instead, residues
comprising the SOD1 dimer interface are spread into discrete re-
gions on each monomer, with a significant fraction solvent-exposed
in the SOD1 trimer (Movie S2). Additionally, the recently discov-
ered epitope of the C4F6 Ab (18), which preferentially binds the
SOD1 trimer (Fig. S4A) as well as several other disease-linked
SOD1 species (15, 16) over the native dimer or monomer, is
completely exposed on the surface of the trimer structure (Fig.
S4B), further supporting our model and suggesting the potential
toxicity of the SOD1 trimer. The atomic coordinates of our SOD1
trimer model are available for download at dokhlab.org.
Mutations in Predicted Monomer–Monomer Interfaces Affect SOD1
Trimer Formation. To verify our model of the SOD1 trimer, we
designed single-residue mutations to the predicted SOD1 trimer
Fig. 1. SOD1 forms nonnative trimer. (A) HS-AFM analysis reveals that un-
der stabilizing conditions (pH 3.5), SOD1 oligomer features a tripartite
structure, in line with volumetric AFM measurements of dry samples, where
oligomer volume is ∼71.7 nm3 and monomer volume is ∼25.3 nm3 (Fig. S1A).
We observe three distinct monomers in HS-AFM recordings at a SOD1 concen-
tration of 30 nM. The three subunits form a nonspherical compact particle,
which is stable over long time periods. (Scale bar: 5 nm.) (B) In destabilizing
conditions (pH 7.4), SOD1 trimers dissociate into three distinct monomers, even
at the high end of physiological concentration (100 nM). (Scale bar: 5 nm.)
Fig. 2. Hybrid experimental/computational method leads to a model of
metastable SOD1 trimer. (A) SOD1 trimer proteolytic cut sites (gray spheres,
shown here on the native dimer structure) in the dimer interface and sec-
ondary structural elements suggest significant structural differences be-
tween native and trimeric structures. (B) Structural model of the metastable
SOD1 trimer obtained using limited proteolysis data as constraints in several
rounds of coarse-grained and atomistic DMD simulations (Fig. S2). (C) Represen-
tation of the SOD1 linear sequence, residues 1–153. Proteolytic cut sites (vertical
lines) determined in limited proteolysis experiments differ significantly in SOD1
monomer (Top), dimer (Middle), and trimer (Bottom), supporting structural
rearrangement during the aggregation process and SOD1 trimer formation.
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interfaces and tested the effects of these mutations on trimer
formation in vitro. Mutations that we predict to stabilize the
SOD1 trimer should result in an increased trimer population,
whereas mutations that we predict to destabilize the trimer
structure should result in a decreased or absent trimer pop-
ulation. Using Monte Carlo energy minimization, we predicted
the change in free energy (ΔΔG) of mutation for all interface
residues to all possible amino acids, and selected for experi-
mental evaluation those mutations having a significant effect
on SOD1 trimer stability (jΔΔGmutj > 3 kcal/mol). To ascertain
that the outcomes of any mutation observed in vitro are caused
by directly affecting SOD1 trimer formation and not due to
stabilization or destabilization of native SOD1 species, we se-
lected only those mutants that feature a negligible effect
(jΔΔGmutj < 1 kcal/mol) on the native SOD1 dimer and
monomer species (Protein Data Bank ID code 1SPD) (Fig. 3).
We observed the aggregation time course of our designed
SOD1 mutants using SEC. All seven of our designed destabi-
lizing mutations successfully decrease or eliminate the pop-
ulation of SOD1 trimer. Upon destabilization of the trimer
interfaces, we observe one of two outcomes: (i) inhibited trimer
formation with resulting increased populations of SOD1 mono-
mer and dimer species or (ii) inhibited trimer formation with a
resulting increase in large aggregates. Exhibiting the first out-
come, in four cases (P62Y-SOD1, G108H-SOD1, I99H-SOD1,
and N65V-SOD1), we observe the formation of a nonnative
extended dimer species, confirmed by AFM (Fig. 3 and Figs. S5
and S6). In the second possible outcome of trimer-destabilizing
mutations, we observe the immediate formation of large aggre-
gates in D101I-SOD1, G147P-SOD1, and N53I-SOD1 (Fig. 3
and Figs. S5 and S6). In these high-aggregation mutants, some
SOD1 trimer is formed in the early hours of the time course,
quickly followed by the appearance of large aggregates. None of
these three trimer-destabilizing mutations form SOD1 trimer,
instead quickly aggregating into large, potentially insoluble ag-
gregates, supporting the hypothesis that large, insoluble aggre-
gates, such as fibrils, lie on a different, competing pathway from
the formation of small, soluble aggregates.
Because the SOD1 trimer is a nonnative, metastable, in-
termediate aggregation state, stabilizing its formation is a much
more challenging task than destabilizing it. In stabilizing one
transient species, we may unknowingly stabilize, destabilize, or
even create another transient species. Although we can account
for the stabilization or destabilization of known structures, such
as the native SOD1 dimer and monomer, aggregation is a complex
process, and we cannot account for other metastable species that
may be perturbed during our mutation of trimer interface residues,
which may affect whether or not we observe increased levels of
SOD1 trimer. Despite these difficulties, we succeeded in predicting
and designing a SOD1 trimer-stabilizing mutant. The F20L-SOD1
mutant demonstrates a clear stabilization of the SOD1 trimer
species: monomer, dimer, and trimer species are all present at time
t = 0, but the trimer species quickly dominates and stabilizes over
t = 24 h, with no larger aggregates forming (Fig. 3). Five additional
mutations predicted to stabilize the SOD1 trimer, while exhibiting a
trimer population, result in stabilization of other nonnative species
ranging from misfolded monomer to protofibrils (Fig. S5), with
stoichiometry confirmed by AFM (Fig. S6). This finding suggests
that the nonnative monomer–monomer interfaces we identify in the
SOD1 trimer are also exploited by other potentially toxic species.
Trimer-Stabilizing SOD1 Mutants Promote Cell Death. Because mu-
tations can cause conformational changes in proteins, especially
when located in a structurally important region like an interface,
SOD1 mutations clinically linked to ALS could cause an entirely
different trimeric species to form, which we would not capture in
our model. Computational testing of the stabilizing effect of each
mutation on all possible SOD1 trimer structures would be pro-
hibitive, and still may not yield an answer to the crucial question:
Do disease mutations cause an increase in the population of
trimeric SOD1? Instead, we address the question of SOD1
trimer disease relevance from another direction: by directly
testing the toxicity of SOD1 trimer in motor neuron-like cells
(NSC-34 cells). We transfected cells with expression constructs
for each of our designed SOD1 mutants, WT SOD1, and A4V-
SOD1, an aggressive ALS-linked mutation responsible for the
majority of familial ALS cases in North America (30, 31), which
we use as a positive control for ALS-relevant cell death. The
A4V mutation has previously been observed to promote the
formation nonnative SOD1 trimer (15). We observed signifi-
cantly increased cell death in NSC-34 hybrid motor neuron cells
expressing A4V-SOD1 (positive control) or our designed trimer-
stabilizing SOD1 mutants (Fig. 4). Conversely, our trimer-
destabilizing mutants do not cause cell death, with cell viability
comparable to cells expressing WT SOD1 (Fig. 4). Similarly,
expression of A4V-SOD1 or trimer-stabilizing SOD1 mutants,
but not trimer-destabilizing SOD1 mutants, resulted in elevated
levels of cleaved caspase-3 compared with WT SOD1 (Fig. 4).
Finally, we note that the amount of cell death present was cor-
related to the stability of the SOD1 mutant trimer (Fig. S7).
Discussion
We conclude that the SOD1 trimer causes cell death in motor
neuron-like cells, and that the nonnative trimeric interfaces ap-
pear to be shared by multiple cytotoxic SOD1 species. Studies
from many groups have suggested potential mechanisms of
SOD1 oligomer neurotoxicity but were unable to characterize
these oligomers fully. Excellent reviews of these mechanisms can
be found elsewhere (32–34). Many of these studies resulted in
Fig. 3. Designed mutations verify the model and demonstrate control of
SOD1 aggregation. Mutations to trimer interface residues designed to stabilize
or destabilize SOD1 trimer but having no effect on SOD1monomer or dimer, are
shown with ΔΔGmut for the trimer, native dimer, and native monomer struc-
tures. Aggregation time courses were measured for each mutant after in-
cubation at physiological concentration (30 μM) and 37 °C for for 0 h (solid line),
2 h (− −), 4 h (− − •), 8 h (− • •), or 24 h (• •). The aggregation of apo-WT SOD1
is shown for comparison, with trimer (T), dimer (D), monomer (M), and large
aggregate (L) peaks labeled when present. Vertical dashed lines between panels
aid comparison of trimer, dimer, and monomer peaks between mutants. We
find that the N65V mutation, predicted to be destabilizing to the SOD1 trimer,
results in a smaller population of trimer than WT, shifting the SOD1 population
toward dimer and monomer formations. The N53I mutation, also predicted to
destabilize SOD1 trimer, results in no detectable SOD1 trimer but, instead, in-
creased populations of large aggregates. The F20L mutation, predicted to sta-
bilize SOD1 trimer, promotes trimer formation early in the aggregation process
and maintains high levels of trimer throughout the experiment. Additional
aggregation time courses can be found in Fig. S5. mAU, milli-absorbance units.
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such broad characterization that we may only conclude that the
toxic SOD1 species was soluble; however, in those studies that
determine a more limited size range, we note that the size of these
oligomers closely mirrors the size of the SOD1 trimer, and we
propose that the trimeric form of SOD1 that we describe in this
work is a likely candidate for the aberrant and detrimental inter-
actions with cellular machinery observed in these previous studies.
Given that SOD1 has been shown to undergo aberrant ag-
gregation in both familial and sporadic ALS (35–37), we propose
that formation of SOD1 trimer is a common pathogenic mech-
anism in ALS, causing the death of motor neurons and progression
of the disease. At the time of writing, 62% of residues known to
feature disease-relevant point mutations are located in the pro-
posed SOD1 trimer interfaces (Table S1 and Dataset S1). More-
over, at least two-thirds of disease mutations located in the trimer
interfaces are overall stabilizing to trimer formation; the effect of
the remaining third cannot currently be established because of the
metastable nature of these oligomers. Due to metastability, the
SOD1 trimer exists as an ensemble of diverse structures (Fig. S4C
and Dataset S1), and although the effect of a mutation on one
trimeric structure may be destabilizing, the same mutation could
promote formation of another trimeric form, resulting in a higher
fraction of disease mutants stabilizing a trimeric form of SOD1.
Recognizing and sequestering SOD1 trimer or preventing its
formation is therefore a potential strategy for preventing neu-
rodegeneration in ALS. Because of the high concentration of
SOD1 in motor neurons (30–100 μM), stoichiometric binding of
a drug compound to native SOD1 may not be a viable option to
abolish trimer formation completely. One option is to stabilize
larger, nontoxic aggregation products; this strategy has been
adopted for amyloid-β aggregates in Alzheimer’s disease, to
positive effect in a cellular model (9). However, another strategy
would involve identifying and blocking toxic interactions of
SOD1 trimer in the cell. Alternatively, the structural knowledge
that we uncover in this work can be used for the design of rec-
ognition and sequestering strategies. The characterization of
structural features, such as the identification of nonnative ag-
gregation interfaces in this work, provides a key step in the
understanding of ALS disease etiology and development of
therapeutic or preventive strategies.
Materials and Methods
Purification of SOD1. For determination of surface-accessible sites in the SOD1
trimer in limited proteolysis studies, we isolated and purified SOD1 from
human erythrocytes, as previously described (26). To generate SOD1 mutants
for aggregation time courses using SEC, and WT SOD1 for comparison of
comparable species, we performed cloning, expression, and purification of
human recombinant SOD1 in Saccharomyces cerevisiae as described elsewhere
(15, 26, 38). We determined the concentration of purified SOD1 species by
measuring the A at 280 nm with an extinction coefficient of 10,800 M−1·cm−1.
We stored samples at −80 °C after flash-freezing in liquid nitrogen.
Formation and Isolation of SOD1 Species. We formed SOD1 trimer by in-
cubating SOD1 dimer at a concentration of 100–120 μM in 50 mM acetate,
150 mM NaCl, and 10 mM EDTA at pH 3.5 for 24 h. We then isolated trimer
and monomer using an AKTA Purifier with a Superdex 200 10/300 GL column
(GE Healthcare) equilibrated in either 50 mM phosphate and 150 mM NaCl
at pH 3.5 (for use with V8 protease) or 50 mM acetate, 150 mM NaCl, and
10 mM EDTA at pH 3.5 (for all other proteases). We isolated monomer species
fresh daily. We obtained trimer fractions from gel filtration chromatogra-
phy, concentrated using an Amicon Ultra filter (Millipore) and used fresh or
stored at 4 °C overnight and used the next day.
AFM. For AFM imaging of dried samples, we immersed freshly cleaved mica
stripes (5.0 × 1.5 cm; Asheville Schoonmaker Mica Co.) in plastic cuvettes
containing 167 μM 1-(3-aminopropyl)silatrane (APS) solution for 30 min (39),
followed by deionized water rinsing and drying in argon flow. We stored
the APS mica in a vacuum chamber for use over the next few weeks (39). We
cut the strips into ∼0.75 × 0.75-cm pieces for sample preparation. We diluted
the SOD1 samples to the appropriate concentrations (3.3–10 nM) with the
corresponding buffers before deposition onto APS mica [50 mM sodium
acetate, 150 mM NaCl, and 10 mM EDTA (pH 3.5) or 20 mM Tris·HCl and
150 mM NaCl (pH 7.4)]. We deposited 20 mL of diluted sample onto APS mica
surfaces for 2 min, followed by thorough rinsing with deionized water and
drying with argon flow. We kept the specimens in a vacuum chamber for at
least 3 h, after which we mounted the specimens onto metal discs with
double-sided tape (carbon-coated; Ted Pella, Inc.). We performed AFM im-
aging on a MultiMode 8 atomic force microscope (Bruker NanoA, Bruker Co.,
Santa Barbara, CA) equipped with PeakForce modulus with microlever
(MSNL; Bruker) probes. We acquired AFM images with 512 × 512 pixels at
a scan rate of 4–6 Hz. We conducted volume and height analysis using
Femtoscan (Advanced Technologies Center). We used “Enum features,” a
functional tool provided by the software, to measure the heights and vol-
umes of the protein in AFM images (40). We measured the background over
the noncovered surface area. We performed Gaussian fitting of the volume
and height values using Origin 6.0 software (Microcal Software, Inc.).
We acquired HS-AFM images using an HS-AFM instrument, operating in
tapping mode in liquid (RIBM). We prepared samples as reported by Miyagi
et al. (41). Briefly, we glued freshly cleaved 1.5-mm mica discs to the glass
rods and modified with 167 μMAPS for 30 min. After rinsing with 20 μL Milli-Q
water (AquaMax-Ultra, LabWater.com, a division of APS water Services
Corporation, Van Nuys, CA) and then three times with 20 μL of pH 3.5 buffer
(50 mM sodium acetate with an additional 150 mMNaCl and 10 mM EDTA), we
deposited the SOD1 samples onto the APS mica in the same buffer. We per-
formed measurements at two different concentrations of SOD1: 100 nM and
30 nM. After 5 min of incubation, we rinsed the surface with the same buffer
used for imaging. To compare the effect of pH on sample dynamics, we removed
the pH 3.5 buffer by pipette and injected the pH 7.4 buffer (20 mM Tris with
150 mM NaCl) to continue sample scanning. We used BL-AC10DS-A2 cantilevers
(Olympus) with carbon tips obtained by electron beam deposition for im-
aging (39). The spring constant of the AFM probes is between 0.1 and 0.2 N/m,
with resonance frequency between 400 and 1,000 kHz in water. We performed
continued scanning over the selected area (50 nm × 50 nm) with a scan rate
of approximately three frames per second. Images contain 128 × 128 pixels.
We processed HS-AFM images using home-built software written by Atsushi
Miyagi, Y.L.L. laboratory, University of Nebraska Medical Center, Omaha, NE.
Fig. 4. SOD1 trimer is cytotoxic. Expression of A4V-SOD1 (positive control)
and trimer-stabilizing mutant SOD1s in NSC-34 motor neuron-like cells in-
creases the incidence of cell death compared with WT SOD1 (negative con-
trol), whereas trimer-destabilizing mutants have no effect on viability.
Applied 3 d posttransfection, red stain [propidium iodide (PI)] identifies
nuclei of dead cells, whereas blue stain (Hoechst) identifies nuclei of all cells.
Incidence of cell death is measured as the percentage of total cells exhibiting
PI staining (left to right from Upper Left): WT, 4%; P62Y, 8%; G108H, 5%;
N53I, 6%; A4V, 23%; H46Q, 29%; K136H, 25%; F20L, 27%; P74G, 24%; and
E21Q, 22%. (Magnification: 20×.) Cell death correlates with trimer stability
with a P value of 0.0476, or a P value of 0.000966 with exclusion of the outlier
P62Y, which is extremely destabilizing (Fig. S7). Elevated levels of the apoptotic
marker cleaved caspase 3 in NSC-34 motor neuron hybrid cells expressing
A4V-SOD1 (positive control) and trimer-stabilizing SOD1 mutants (demon-
strated by Western blot, Lower Right) confirm increased cytotoxicity of these
mutants compared with WT SOD1 (negative control) and trimer-destabilizing
SOD1 mutants.
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Limited Proteolysis. We performed limited proteolysis at 25 °C in 100 mM
buffer (acetate, phosphate, or Tris) at the appropriate pH for each enzyme:
V8 protease reactions in 100 mM phosphate buffer (pH 4.0), chymotrypsin
reactions in 100 mM Tris 50 mM CaCl2 buffer (pH 7.8), and pepsin reactions
in 100 mM acetate buffer (pH 3.5), quenched by addition of 1 M Tris buffer
(pH 8.0) to a final concentration of 150 mM. We performed 1- to 50-min time
course proteolysis reactions for trimer, allowing the reaction to proceed for
a sufficient time to allow a single proteolytic cut and no more than four
proteolytic cuts: 1 min for V8 and pepsin reactions and 2 min for chymo-
trypsin reactions. This technique preserves the structural integrity of the
trimer during the period of the limited proteolytic reaction, ensuring rele-
vance of the obtained structural information. Time course reactions
for monomer and dimer extended longer, as is necessary to obtain SOD1
cleavage. The proteolysis reaction for dimer contained an equimolar SOD1
concentration to the trimer reaction (7–15 μM), but we performed reactions
with SOD1 monomer at the concentration eluted from the FPLC (2.6–5 μM),
because we could not concentrate the monomer without significant ag-
gregation. We determined protease/SOD1 ratios empirically. We quenched
samples by the addition of 100 mM PMSF (1 mM final) and froze them until
ready for further use. We desalted samples using Ziptip C18 pipette tips
(Millipore) and eluted the peptides in 20 μL of MS grade solvent [50% ace-
tonitrile, 50% water, and 0.1% TFA (vol/vol); Fisher].
MS. We performed MS on an AB SCIEX 4800 PLUS MALDI-TOF-TOF instrument
at the University of North Carolina Michael Hooker Proteomics Center using
α-cyano-4-hydroxycinnamic acid as the matrix. Data output was analyzed in
Data Explorer, with the signal-to-noise ratio set to 20–30, MS/MS tolerance set
to ±1 Da, and peptide charge set to 1+. We identified peptides using Mascot
(Matrix Science) (42) with the UniProt database, with the search limited to the
taxonomy Homo sapiens. We used the data from the earliest time points that
resulted in cleavage (1–2 min) for constraints in modeling (Table S2).
Incorporation of Experimental Constraints. To incorporate information from
limited proteolysis experiments into DMD simulations, we created an algo-
rithm for converting knowledge of the sequence positions of proteolytic
cleavage sites into pairwise simulation constraints (Fig. S2). The formation of
trimeric SOD1 is made possible by a perturbation to the native state, which
must occur as local unfolding in a background of native interactions. To
account for this phenomenon, we first represent the native background as a
Go¯ potential (43), which rewards contacts that are present in the native
structure, assigning a pairwise attraction of 1 kcal/mol between pairs of
residues with a distance between beta-carbons that is less than 7.5 Å. Next,
we define a bias potential based on the location of proteolytic cleavage
sites. Because each cleavage site must necessarily be (i) solvent-exposed and
(ii) unstructured, we assign a repulsive interaction of energy E0 between
the cleavage site j and every other residue in the system. Because residues
near a solvent-exposed site are also likely to be solvent-exposed, and because an
unstructured region of ∼12 residues surrounding the cleavage site is necessary
for the proteolytic enzyme to gain access to the site (27, 44), we apply a stepwise,
decreasingly repulsive potential to the two residues on either side of each
cleavage site, such that the pairwise repulsive interaction of the respective resi-
due with each residue in the system has energy:
ErðiÞ=
X
j∈cleavage  sites
E0 expð−ji− jj=2Þ, whereji− jj≤2.
For each identified cleavage site, we thus generate 5n pairwise constraints,
where n is the total number of residues in the system. All Go¯ and experi-
mental constraint potentials are additive. Thus, the combined potential
function is:
H=−
X
i<j
Δij•δijE0 + λ
X
i<j
δijððErðiÞ+ErðjÞÞ=2Þ,
where Δij is the native contact matrix of the conformation, δij is the contact
matrix of the current conformation, and λ is a scaling parameter discussed in
the next section.
Parameterization of Bias Potential. To scale the two terms of our bias po-
tential, we tested the effects of various values of λ from 0.0 to 30 at intervals
of 0.3 (from 0.0 to 3.0) or 3 (from 3 to 30) in coarse-grained (45) replica
exchange simulations of apo-SOD1 monomer, which features a well-defined
folding pathway. We examined the resulting energetic profiles and folding
trajectories, and selected values of λ for which folding intermediates are
introduced by the competition between Go¯ and experimental energy terms
but distinct folding transitions are evident. At λ = 0 (Go¯ potential only), we
find a single, sharp folding transition with no intermediates, as expected
from experimental findings (46). At λ ≥ 1.5, we cannot resolve individual
thermodynamic transitions, and protein unfolding occurs with increasing
linearity as λ increases. We find that that λ values 0.33 ≤ λ ≤ 1.2 fit our cri-
teria for selection, and that values in this range produce nearly identical
final structures in our test apo-monomer system (Fig. S3). We therefore se-
lected λ = 0.99 for use in modeling of trimeric SOD1.
Coarse-Grained DMD. To obtain initial trimeric SOD1 structures that agree
with experimental data, we use DMD (47, 48) replica exchange (REX) (49)
simulations. We apply our bias potential to a coarse-grained model of three
natively folded SOD1 apo-monomers placed in proximity to each other but
not initially bound. We use a four-bead protein model (45) for increased
sampling and for simplified application of the bias potential to the Cβ bead
of each residue, with the exception of Ala, for which the bias potential is
applied to the Cα bead. For each value of λ, we determined the ideal number
of replicas and spread of replica temperatures such that we sample energetic
space spanning the entire melting transition and that exchange of replicas
occurs with an acceptance rate between 0.2 and 0.7, with exchange
attempted every 1,000 time steps. For λ = 0.99, we used 27 replicas, with
temperatures of 0.435, 0.445, 0.455, 0.462, 0.470, 0.480, 0.490, 0.503, 0.513,
0.523, 0.538, 0.552, 0.566, 0.581, 0.595, 0.610, 0.625, 0.639, 0.654, 0.674,
0.694, 0.713, 0.733, 0.753, 0.768, 0.788, and 0.815 kcal·mol−1·kB
−1. We per-
formed simulations for 106 time steps.
We evaluated the experimental agreement of each structure snapshot from
simulation by calculating the average number of contacts made by each pro-
teolytic cut site residue (Nc). Our rationale is that to demonstrate agreement
with limited proteolysis results, each proteolytic cut site residue should make as
few contacts with other residues as possible, because its ability to be cleaved by
proteolytic enzymes denotes its solvent accessibility and lack of participation in
secondary structure interactions. However, although the proteolytic cleavage
sites should demonstrate a minimum of structural interaction, SEC results (15)
indicate that the structure should be a compact, associated trimer. We there-
fore use a combination of proteolytic cut site contacts and trimer radius of
gyration (Rg) to select a pool of candidate structures from all REX simulation
trajectories. When we examined these two criteria together, we found a cluster
of structures having Nc < 1.5 and Rg < 30 Å. We clustered this pool of candidate
structures by pairwise rmsd, and selected the centroid of the largest cluster for
further simulation and structural refinement.
All-Atom DMD. We reconstructed the four-bead centroid structure obtained
from the DMD REX simulations described above to an all-atom model (29)
and performed structural minimization using Chiron (50) to remove clashes
introduced by reconstruction. To equilibrate our structure in a physical force
field, we first performed low-temperature (below the melting transition) all-
atom REX simulations using 26 replicas with temperatures of 0.350, 0.360,
0.370, 0.380, 0.390, 0.400, 0.410, 0.420, 0.430, 0.440, 0.450, 0.460, 0.470,
0.480, 0.490, 0.500, 0.510, 0.520, 0.530, 0.540, 0.550 0.560, 0.570, 0.580,
0.590, and 0.600 kcal·mol−1·kB
−1. We selected the ideal number of replicas
and spread of replica temperatures such that exchange of replicas occurs
with an acceptance rate between 0.2 and 0.7, with exchange attempted
every 1,000 time steps. We performed simulations for 106 time steps. We
isolated the lowest energy structure from all simulation replicas, and con-
tinued simulation of that structure at a temperature of 0.350 kcal·mol−1·kB
−1
for an additional 106 time steps. Finally, we selected the lowest energy
structure from this single-temperature trajectory as our final model, and
verified the quality of the model using Gaia (51).
Computational Mutagenesis. Using our final SOD1 trimer model, we per-
formed computational mutagenesis of every residue residing in an interface
between monomer chains. We designate a residue as residing in an interface
if any atom of that residue is within 4.5 Å of any atom of a residue belonging
to a different monomer chain. We performed computational mutagenesis of
each interface residue to every possible residue and calculated the change in
free energy upon mutation (ΔΔGmut) using Eris (52, 53). Due to complexity in
their interactions, we did not perform mutations to Cys.
SOD1 Aggregation Time Course Experiments.We used time-resolved analytical
SEC to measure the relative population sizes of the various SOD1 species over
time. We diluted purified mutant and WT SOD1 to 30 μM and incubated
them at 37 °C at time 0 (t = 0). At designated time points (t = 0, t = 2, t = 4,
t = 8, t = 24), we withdrew and filtered aliquots of each sample, and sep-
arated SOD1 species by SEC at 4 °C using an AKTA Purifier with a Superdex
200 10/300 GL column (GE Healthcare) equilibrated in 50 mM acetate, 150 mM
NaCl, and 10 mM EDTA (pH 3.5).
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Measurement of Cytotoxicity of SOD1 Trimer. We maintained neuroblastoma
spinal cord hybrid cell lines (NSC-34) in DMEM containing 10% (vol/vol) FBS.
We plated ∼5,000 NSC-34 cells in one well of a 24-well plate with differen-
tiation medium [1% FBS, 1% nonessential amino acid supplement, (vol/vol)
10 μM of RA]. After a 2-d differentiation period in DMEM, we transfected cells
with 2 μg of plasmid encoding WT SOD1 or SOD1 mutants (within the pCI-Neo
vector) using Lipofectamine 3000 (Thermo Fisher Scientific) according to the
manufacturer’s instructions. To verify that SOD1 had been properly trans-
fected, we performed immunostaining. We fixed cells 24 h posttransfection
using 4% (vol/vol) PFA for 10 min at room temperature. We blocked with
3% (vol/vol) goat serum, followed by Abs against SOD1 (Sigma) and Hoechst
33342 counterstain. We performed propidium iodide (red) and Hoechst (blue)
staining in culture 3 d posttransfection without fixation. We performed a
Western blot with ∼20,000 cells per well, collecting cells 2 d posttransfection.
We lysed cells in PBS with 0.5% Triton X-100, 0.5 mM EDTA, and EDTA-free
protease inhibitor (Roche Life Sciences). We denatured cell lysates and
resolved using 18% (vol/vol) SDS/PAGE, and incubated with Abs against
cleaved caspase-3 (Cell Signaling Technology), SOD1 (Calbiochem), and GAPDH
(Chemcon), followed by secondary Ab incubation. We visualized protein bands
using an Odyssey IR imaging system (LI-COR Biosciences). Cell viability was not
assayed in all mutants because we were unable to verify SOD1 transfection in
five of our predicted mutants, four of which are trimer-destabilizing muta-
tions: D124Q-SOD1, G147P-SOD1, I99H-SOD1, D101I-SOD1, and N65V-SOD1.
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